The two groups significantly differed in 3-year disease-free survival (pCR group: 100%; non-pCR group: 59.0%; P = 0.039); pCR was significantly affected by histological grade, PR status, Ki67 index, primary tumor size, clinical staging, and number of trastuzumab cycles. Here, PGR is linked to neoplasm.